A personalized medicine specialist raised £ 50 million in Series B funding.
Based at Chesterford Research Park near Cambridge, Microbiotica has developed technology that uses the trillions of bacteria in the body, known as the microbiome, to discover and develop therapeutic drugs and biomarkers for a range of ailments and diseases.
The company’s current areas of focus are cancer immunotherapy and inflammatory bowel disease, and it has established important clinical and academic partnerships in these areas.
The round was led by Flerie Invest and Tencent and included British Patient Capital, Cambridge Innovation Capital, IP Group and Seventure Partners.
“This major fundraiser is a substantial validation of both our team and our world-leading technology,” said Mike Romanos, co-founder and CEO of Microbiotica.
“We are fortunate to have the support of new and existing investors who have recognized the importance of the therapeutic potential of the microbiome and the unique capabilities of Microbiotics.
“With this additional investment, we will be able to conduct clinical trials with our leading products in immuno-oncology and ulcerative colitis. We will also expand our portfolio of microbiome-based products that have the potential to benefit patients globally. ”
Judith Hartley, CEO of British Patient Capital, added: “Microbiotics is a highly innovative British company operating in the very important field of microbiome biology.
“Through its bioinformatics platform, it is generating therapeutic treatments aimed at immuno-oncology and ulcerative colitis. It has a number of drug development programs that are progressing towards clinical trials.
“British Patient Capital, through our Future Fund: Breakthrough program, is proud to support this world-class team as it continues to explore and commercialize this exciting new area of medicine.”
£ 50 million to feed a personalized medicine specialist
Source link £ 50 million to feed a personalized medicine specialist